| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于治疗痤疮和其它病症的内脂素治疗药物 | CN201080008874.1 | 2010-01-06 | CN102325789A | 2012-01-18 | 他玛·特南鲍姆; 罗拉·布赖曼-维克斯曼; 雷威托·曼迪尔-莱文 |
| 本申请涉及治疗痤疮和其它病症的组合物和方法。尤其是，所述组合物和方法用于治疗皮脂有关的病症。 | ||||||
| 2 | 增强癌症疗法的方法和组合物 | CN201580050294.1 | 2015-07-17 | CN107073027A | 2017-08-18 | 安东尼奥·费尔南德斯·桑蒂德里安; 布伦希尔德·H·费尔丁 |
| 本发明提供了用于增强抗激素治疗的效力或用于预防治疗后的癌症复发或进展的方法和组合物。本发明还提供了使治疗抗性的癌细胞或患有难治的癌细胞的患者再敏化或敏化以继续或开始抗激素治疗的方法。本发明还提供了用于在抗激素治疗后预测或诊断抗激素治疗效果或癌症复发或转移的可能性的方法。 | ||||||
| 3 | 制备交联NAMPT及筛选NAMPT抑制剂的方法 | CN201410061169.8 | 2014-02-24 | CN103898076A | 2014-07-02 | 董旭; 唐淳 |
| 本发明公开了一种制备交联NAMPT及筛选NAMPT抑制剂的方法，涉及抑制剂领域，包括以下步骤：制备NAMPT重组蛋白，使用还原剂还原NAMPT重组蛋白，还原蛋白与交联剂反应获得活性中心被封堵的交联NAMPT，配置第一蛋白溶液、和第二蛋白溶液，制备第一待分析溶液、第一对照溶液、第二待分析溶液和第二对照溶液，采用荧光光谱仪分别测定第一待分析溶液、第一对照溶液、第二待分析溶液和第二对照溶液的荧光强度，并计算第一待分析溶液和第二待分析溶液荧光强度下降的百分率。本发明的步骤比较少，操作较简单，成本比较低，反应过程受外界环境影响比较小，不仅重复性较好，而且结果比较准确。 | ||||||
| 4 | 用于治疗痤疮和其它病症的内脂素治疗药物 | CN201310291486.4 | 2010-01-06 | CN103800903A | 2014-05-21 | 他玛·特南鲍姆; 罗拉·布赖曼-维克斯曼; 雷威托·曼迪尔-莱文 |
| 本申请涉及治疗痤疮和其它病症的组合物和方法。尤其是，所述组合物和方法用于治疗皮脂有关的病症。 | ||||||
| 5 | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 | JP2014196409 | 2014-09-26 | JP6140120B2 | 2017-05-31 | テンネンバウム,タマール; ブライマン‐ウィクスマン,リオラ; マンディル‐レヴィン,リヴァイタル |
| 6 | VISFATIN THERAPEUTIC AGENTS FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS | EP10745884.6 | 2010-01-06 | EP2400980A2 | 2012-01-04 | TENNENBAUM, Tamar; BRAIMAN-WIKSMAN, Liora; MANDIL-LEVIN, Revital |
| The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions. | ||||||
| 7 | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 | JP2014196409 | 2014-09-26 | JP2015051973A | 2015-03-19 | TAMAR TENNEBAUM; BRAIMAN-WIKSMAN LIORA; REVITAL MANDIL-LEVIN |
| 【課題】皮脂産生に関連する挫瘡(にきび)及びその他の状態を治療するのに役立つビスファチン活性を調節させる改良された組成物および方法の提供。【解決手段】ビスファチン活性剤および薬学的に許容される希釈剤またはアジュバントを含む医薬組成物。好ましい実施形態では、送達用ペプチドが該薬学的に許容される担体を伴って、または伴わずに、ビスファチン活性剤と組み合わせて使用される。被験者における皮脂過剰生成状態を治療する方法、被験者における尋常性挫瘡を治療する方法及び、被験者における皮脂産生欠乏症状態を治療する方法であって、被験者に各々の症状に対する治療有効量のビスファチンアゴニスト又はビスファチンアゴニストを含有する医薬組成物を投与する工程を含む、各々の状態を治療する方法である。【選択図】なし | ||||||
| 8 | Visfatin therapeutic agents for the treatment of acne and other conditions | JP2011550698 | 2010-01-06 | JP2012518630A | 2012-08-16 | テンネンバウム，タマール; ブライマン‐ウィクスマン，リオラ; マンディル‐レヴィン，リヴァイタル |
| The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions. | ||||||
| 9 | VISFATIN ANTAGONISTS AGENTS FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS | EP10745884.6 | 2010-01-06 | EP2400980B1 | 2016-08-31 | TENNENBAUM, Tamar; BRAIMAN-WIKSMAN, Liora; MANDIL-LEVIN, Revital |
| 10 | VISFATIN THERAPEUTIC AGENTS FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS | EP10745884 | 2010-01-06 | EP2400980A4 | 2013-03-27 | TENNENBAUM TAMAR; BRAIMAN-WIKSMAN LIORA; MANDIL-LEVIN REVITAL |
| 11 | Targeting NAD+ to Treat Chemotherapy and Radiotherapy Induced Cognitive Impairment, Neuropathies and Inactivity | US15570210 | 2016-04-28 | US20180125871A1 | 2018-05-10 | Lindsay Wu; David A. Sinclair |
| Methods and compositions for preventing or treating peripheral neuropathy, cognitive deficits, inactivity, depression, chemotherapy and/or radiotherapy induced peripheral neuropathy and cognitive deficits, and improving cognitive performance, in a subject in need thereof are disclosed. The disclosed methods include the step of administering to the subject an effective amount of an agent that increases the level of NAD+ in the subject. | ||||||
| 12 | NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation | US14434573 | 2013-10-09 | US09877981B2 | 2018-01-30 | David A. Sinclair; Ana P. Gomes; Lindsay Wu |
| Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods.Methods and compositions are provided for the treatment of diseases or disorders associated with mitochondrial dysfunction.The invention relates to methods for treatment and prevention of cancer by administering agents that increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis. | ||||||
| 13 | NAD BIOSYNTHESIS AND PRECURSORS IN THE PREVENTION AND TREATMENT OF INFLAMMATION | US14434614 | 2013-10-09 | US20150265642A1 | 2015-09-24 | David A. Sinclair; Ana P. Gomes |
| Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods.Methods and compositions are provided for the treatment of diseases or disorders associated with mitochondrial dysfunction.The invention relates to methods for treatment and prevention of disorders associated with inflammation by administering agents that increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis. | ||||||
| 14 | VISFATIN THERAPEUTIC AGENTS FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS | US14474142 | 2014-08-31 | US20150065432A1 | 2015-03-05 | TAMAR TENNENBAUM; LIORA BRAIMAN-WIKSMAN; REVITAL MANDIL-LEVIN |
| The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions. | ||||||
| 15 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) MUTANT AND USE THEREOF | US15574849 | 2016-07-30 | US20180230443A1 | 2018-08-16 | Rongzhao FU; Qi ZHANG |
| The present invention discloses a Nicotinamide phosphoribosyltransferase (nampt) mutant and use thereof. The present invention relates to a nicotinamide phosphoribosyltransferase (Nampt) mutant artificially obtained through genic site-directed mutation. An object of the present invention is to provide a Nampt mutant having a catalytic activity higher than that of a conventional wild type parent, wherein the enzymatic activity of the Nampt mutant provided in the present invention is 1.2-6.9 times of the enzymatic activity of the parent. | ||||||
| 16 | METHOD FOR PREPARING NICOTINAMIDE MONONUCLEOTIDE (NMN) | US15574851 | 2016-07-30 | US20180162895A1 | 2018-06-14 | Rongzhao FU; Qi ZHANG |
| The present invention provides a method for preparing nicotinamide mononucleotide (NMN) by biocatalysis. The method includes a step of catalytically reacting a plurality of raw materials including nicotinamide, ATP, and ribose in the presence of nicotinamide phosphoribosyltransferase (Nampt), ribose phosphate pyrophosphokinase, and ribokinase, to prepare the NMN. | ||||||
| 17 | Aptamers screening method based on graphene without target immobilization and the aptamers obtained from the method | US15066514 | 2016-03-10 | US09562907B2 | 2017-02-07 | Man Bock Gu; Jee Woong Park; Tatavarty Rameshwar |
| Provided is aptamers screening method based on graphene without target immobilization and the aptamers obtained from the method, and more particularly, a new GO-SELEX method without target immobilization in which a single-stranded nucleic acid pool may react with a non-bound target material or a counter-target material, after which a single-stranded nucleic acid which has not been bound to the target or counter-target may be separated by using the graphene. Also, the specific aptamer obtained through the above-described method may be used for diagnosing target related diseases. | ||||||
| 18 | Visfatin therapeutic agents for the treatment of acne and other conditions | US14474142 | 2014-08-31 | US09393284B2 | 2016-07-19 | Tamar Tennenbaum; Liora Braiman-Wiksman; Revital Mandil-Levin |
| The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions. | ||||||
| 19 | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof | US13533686 | 2012-06-26 | US20120328526A1 | 2012-12-27 | Tibor Kristian |
| The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD+ glycohydrolase activity. | ||||||
| 20 | 化学療法及び放射線療法誘発性認知機能障害、神経障害及び不活動を治療するためのＮＡＤ＋の標的化 | JP2017556614 | 2016-04-28 | JP2018514548A | 2018-06-07 | シンクレア,デビッド,エー.; ウー,リンゼイ |
| それを必要とする被験体における末梢神経障害、認知欠損、不活動、抑鬱、化学療法及び/又は放射線療法誘発性末梢神経障害及び認知欠損を予防又は治療し、認知パフォーマンスを改善する方法及び組成物が開示される。開示される方法は、被験体におけるNAD+のレベルを増加させる薬剤の有効量を被験体に投与するステップを含む。【選択図】図1 | ||||||
QQ群二维码
意见反馈
意见反馈